{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-029787","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2022-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.805735+00:00","generated_at":"2026-06-27T10:38:16.361911+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Coherus appoints Dr. Lee Newcomer to board; Dr. James Healy resigns","bullets":["Appointed Dr. Lee Newcomer to Board effective Feb 2; receives option for 54k shares plus $50k annual retainer.","Newcomer is former UnitedHealth CMO, brings oncology and payer expertise to board.","Director James Healy resigned Feb 4; departure not due to any disagreement.","Mark Stolper reclassified from Class III to Class II to equalize board class sizes.","Board expanded to 7 members; now 2 directors per class."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-029787","json":"https://secwatch.observer/filing/0001193125-22-029787.json","markdown":"https://secwatch.observer/filing/0001193125-22-029787.md","text":"https://secwatch.observer/filing/0001193125-22-029787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000119312522029787/0001193125-22-029787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000119312522029787/d298250d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T10:38:16.361911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b012df3c73","claim":"Lee N. Newcomer was appointed as Director at Coherus Oncology, Inc..","evidence_excerpt":"On February 2, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) increased the size of the Board from six directors to seven directors and appointed Dr. Lee N. Newcomer to fill the vacancy created by such increase.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000119312522029787/0001193125-22-029787-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e59551f7e2","claim":"James I. Healy resigned as Director at Coherus Oncology, Inc..","evidence_excerpt":"On February 4, 2022, James I. Healy, M.D., Ph.D. resigned from the Board of the Company, effective immediately upon notice of his resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000119312522029787/0001193125-22-029787-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}